A $28.1 million Series A funding round headed by Celadon Partners is secured by GDMC

Genetic Design and Manufacturing Corporation (GDMC) has successfully secured $28.1 million in Series A investment, with Celadon Partners leading the founding round. Based in Singapore, GDMC, a prominent biotech company, aims to utilize the funds to support cutting-edge technology and enhance process efficiency, thereby further reducing manufacturing costs for partners involved in advancing medications through clinical trials and towards commercialization.

The Series A fundraising round saw participation from key investors, including NSG Ventures, WI Harper Group, and SEEDS Capital, highlighting the strong support and confidence in GDMC's innovative initiatives. The company envisions leveraging the financial infusion to advance its mission of providing state-of-the-art solutions in the field of cell, gene, and nucleic acid therapies (CGNT).

Notably, GDMC is in the process of constructing a 155,000 square foot facility dedicated to pre-clinical, clinical, and commercial activities related to CGNT. This facility is poised to play a pivotal role in supporting the development and production of groundbreaking therapies. The company plans to roll out the clinical and commercial facilities in a phased manner between 2024 and 2027, with reservations currently being accepted. GDMC has already secured its first clients, marking a significant step in its journey towards establishing itself as a leader in the biotech industry.

By securing Series A investment and building advanced facilities, GDMC not only fortifies its position in the biotech sector but also contributes to Singapore's growing prominence in the field of innovative therapies. The company's commitment to driving advancements in CGNT and facilitating the commercialization of medications underscores its dedication to improving healthcare outcomes and pushing the boundaries of biotechnological innovation.